SCHEMBL21295528

SCHEMBL21295528

COc1cc(Oc2ccccc2)ccc1-n1c(=O)[nH]c(=O)n(-c2ccccc2)c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 14/20 1.00
NTRK2 Q16620 14/20 1.00
IGF1R P08069 5/20 1.00
FGFR1 P11362 5/20 1.00
NTRK3 Q16288 10/20 0.67
HSD17B10 Q99714 2/20 0.51
PKM P14618 1/20 0.51
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 1/20 0.46
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30743936 1.00 NTRK1 (1.00) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL30743935 0.85 NTRK1 (0.74) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL21295389 0.85 NTRK1 (0.74) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL21295397 0.83 NTRK1 (0.71) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL30743943 0.83 NTRK1 (0.71) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL21295403 0.82 NTRK1 (1.00) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL21295517 0.82 NTRK1 (0.84) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL21295405 0.81 NTRK1 (1.00) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL21305534 0.80 NTRK1 (1.00) NTRK1NTRK2IGF1RFGFR1NTRK3
SCHEMBL30743954 0.80 NTRK1 (1.00) NTRK1NTRK2IGF1RFGFR1NTRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2025-07-03 US claimed
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN claimed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP claimed
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2025-07-03 US disclosed
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed
EP-3759088-B1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2023-01-25 EP disclosed
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2022-09-29 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins AlzeCure Pharma AB (SE) 2022-06-07 US disclosed
EP-3759088-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS Alzecure Pharma AB (SE) 2021-01-06 EP disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2020-12-24 US disclosed
CN-111819172-A Triazine derivatives for the treatment of neurotrophin-related disorders 阿泽克制药公司 2020-10-23 CN disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed
WO-2019162702-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 15/4885NTRK2 1/4885IGF1R 127/4885
US-20250214948-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 15/4885NTRK2 1/4885IGF1R 127/4885
US-11352332-B2 Triazine derivatives for treating diseases relating to neurotrophins NTRK2, BDNF, NGF NTRK1 13/4885NTRK2 1/4885IGF1R 83/4885
US-20200399230-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF NTRK1 13/4885NTRK2 1/4885IGF1R 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.